This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feil, P. D. Articles by Satyaswaroop, P. G. Search for Related Content PubMed PubMed Citation Articles by Feil, P. D. Articles by Satyaswaroop, P. G.

Progesterone Receptor Structure and Protease Activity in Primary Human Endometrial Carcinoma¹

Department of Obstetrics and Gynecology and Cancer Research Center, The Milton S. Hershey Medical Center of The Pennsylvania State University, Hershey, PA 17033

Monoclonal antibodies were used to investigate progesterone receptor structure (isoforms) in 33 primary human endometrial tumors. The monoclonal antibodies recognized on protein blots two progesterone receptor proteins with molecular weights of 116,000 and 81,000. The M_r 116,000 protein appeared as a triplet, while a single band was found for the M_r 81,000 protein. The triplet/singlet structure was found in all progesterone receptor-positive tumors, regardless of the degree of tumor differentiation. Protease activity, which gave rise to a false-negative pattern on protein blots, was found in approximately one-half of the tumors in which it was investigated. Inclusion of a cocktail of protease inhibitors during sample preparation resulted in the maintenance of the triplet/singlet progesterone receptor structure. Mixing experiments using a progesterone receptor-rich human endometrial carcinoma (EnCa 101), which lacks protease activity, and protease-containing primary tumor homogenates indicated that the protease was leupeptin sensitive. Interestingly, while the proteolytic activity reduced or eliminated the triplet/singlet progesterone receptor structure seen on protein blot analysis, it did not affect progesterone receptor concentration measured by Scatchard analysis. Sample preparation in the presence of protease inhibitors is therefore a requisite for structural analysis of the progesterone receptor in endometrial tumors.

¹ This work was supported by National Cancer Institute Grant POI-CA 40011.

² To whom requests for reprints should be addressed.

³ Present address: Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, NSW 2010, Australia.

Received 8/12/87. Revised 11/18/87. Accepted 12/ 2/87.

This article has been cited by other articles:

				O. M. Conneely, J. P. Lydon, F. De Mayo, and B. W. O'Malley Reproductive Functions of the Progesterone Receptor Reproductive Sciences, January 1, 2000; 7(1_suppl): S25 - S32. [Abstract] [PDF]

				C. Yeates, S. M. N. Hunt, R. L. Balleine, and C. L. Clarke Characterization of a Truncated Progesterone Receptor Protein in Breast Tumors J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 460 - 467. [Abstract] [Full Text]